This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Serenoa repens ( saw palmetto ) in treatment of benign prostatic hyperplasia

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

  • Serenoa repens, also called 'saw palmetto', (from the American dwarf plant) is a herbal therapy for management of lower urinary tract symptoms
  • there is conflicting evidence concerning the use of Serenoa repens in treatment of lower urinary tract symptoms in benign prostatic hyperplasia (1,2,3)
    • a systematic review stated that evidence suggested that treatment with Serenoa repens results in mild-to-moderate improvements in urinary symptoms and flow measures (2)
    • however a double-blind randomised controlled trial of men over the age of 49 years who had moderate-to-severe symptoms of benign prostatic hyperplasia to one year of treatment with saw palmetto extract (160 mg twice a day) or placebo did did not improve symptoms or objective measures of benign prostatic hyperplasia (3)

Notes:

  • the long-term safety of this treatment has not been assessed

Reference:

  1. Drug and Therapeutics Bulletin (2003), 41 (3), 18-21.
  2. Wilt T et al. Serenoa repens for benign prostatic hyperplasia (Cochrane Review). In: The Cochrane Library, issue 1, 2003. Oxford: Update Software [Last substantive update 20 March 2002].
  3. Bent S et al. Saw palmetto for benign prostatic hyperplasia. NEJM 2006;354:557-66.

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.